Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
250.22B
Market cap250.22B
Price-Earnings ratio
15.58
Price-Earnings ratio15.58
Dividend yield
2.17%
Dividend yield2.17%
Average volume
12.59M
Average volume12.59M
High today
$56.94
High today$56.94
Low today
$55.82
Low today$55.82
Open price
$56.42
Open price$56.42
Volume
7.54M
Volume7.54M
52 Week high
$119.09
52 Week high$119.09
52 Week low
$45.05
52 Week low$45.05

NVO News

Benzinga 45m
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporati...

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
Benzinga 45m
Omeros Skyrockets On $2.1B Novo Nordisk Rare Disease Deal - Novo Nordisk, Omeros - Benzinga

...

Omeros Skyrockets On $2.1B Novo Nordisk Rare Disease Deal - Novo Nordisk, Omeros - Benzinga
Investor's Business Daily 3h
Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk

Omeros (OMER) stock catapulted to a 10-month high Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment for rare b...

Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk

Analyst ratings

59%

of 32 ratings
Buy
59.4%
Hold
34.4%
Sell
6.3%

More NVO News

Nasdaq 3h
Omeros Stock Soars 149% After $2.1 Billion Deal With Novo Nordisk

(RTTNews) - Omeros Corporation (OMER) surged 148.54% to $10.19, up $6.09, after announcing a $2.1 billion licensing and asset purchase deal with Novo Nordisk fo...

Omeros Stock Soars 149% After $2.1 Billion Deal With Novo Nordisk
Nasdaq 6h
Novo Nordisk Signs Purchase And License Deal For Omeros's Zaltenibart

(RTTNews) - Novo Nordisk A/S (NVO), along with Omeros Corp., Wednesday announced a definitive asset purchase and license agreement for the candidate drug zalten...

Novo Nordisk Signs Purchase And License Deal For Omeros's Zaltenibart
The Wall Street Journal 6h
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

Novo Nordisk will take over a drug being developed to treat rare blood and kidney disorders from Omeros. tom little/Reuters Novo Nordisk NOVO.B -0.14 %decrease...

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
TipRanks 7h
Omeros Signs Major Deal with Novo Nordisk

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

The Motley Fool 12h
Meet the 1.4% Yield Dividend Stock That Could Soar in 2026

The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value. Danish pharmaceutical giant Novo No...

Meet the 1.4% Yield Dividend Stock That Could Soar in 2026
TipRanks 1d
Novo Nordisk price target raised to $55 from $50 at BMO Capital

BMO Capital analyst Evan Seigerman raised the firm’s price target on Novo Nordisk (NVO) to $55 from $50 and keeps a Market Perform rating on the shares ahead of...

Nasdaq 2d
Why Scholar Rock Stock Got Socked on Monday

Key Points A third-party manufacturing facility has apparently been flagged by the FDA. The plant is owned by pharmaceutical industry peer Novo Nordisk. 10 s...

Why Scholar Rock Stock Got Socked on Monday
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.